ASPEN-06 AT148006


A Phase 2/3 Study of ALX148 in Patients with Advanced HER2- Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Trial summary:

A Phase 2/3 Study of ALX148 in Patients with Advanced HER2- Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

Receptor status / problem studied:

Inclusion criteria

1) HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line).

2) Adequate Bone Marrow Function.

3) Adequate Renal & Liver Function.

4) Adequate Performance Status.

Exclusion criteria

1) Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.

2) Prior treatment with any anti-CD47 or anti-SIRPĪ± agent.

3) Prior treatment with ramucirumab.

View more trial information

Open for recruitment

Trial Title

ASPEN-06 / AT148006

Diagnosis

Gastric / gastroesophageal cancer

Type of trial

Pharmaceutical

Type of treatement

Medical Oncology

Phase

II/III

Locations

Investigators

Principal Investigator
View all clinical trials

Search

Contact us
Become a patient